All In Biotech

Drug Trial Radar · NCT06721871

Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID)

Evaluation of Safety, Tolerability and Efficacy of Crofelemer Following Multiple Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Participants With Microvillus Inclusion Disease (MVID)

Last checked: Nov 20, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

6

Actual

Start

May 1, 2025

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Napo Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Dec 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study that will evaluate the safety, tolerability and preliminary efficacy of multiple ascending doses of crofelemer, compared to placebo, using a randomized cross-over design within each dose level, when administered to participants with MVID receiving parenteral support (PS, defined as TPN with or without supplementary IV fluid requirements). Blinded study drug will be administered as a novel crofelemer formulation, Crofelemer Powder for Oral Solution, or a matching placebo powder formulation for oral solution. Assigned study drug will be reconstituted and administered orally (or enterally) three times daily (TID) as a concentrated liquid formulation in each of the three dose levels.

Conditions

  • Microvillus Inclusion Disease
  • Congenital Disorders
  • Rare Diseases

Interventions

  • Crofelemer Powder for Oral SolutionDrug

    Crofelemer Powder for Oral Solution

  • Placebo Powder for Oral SolutionDrug

    Matching Placebo Powder for Oral Solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and TolerabilityTime frame: 32 Weeks
  2. Changes in Physical ExaminationTime frame: 32 Weeks
  3. Changes in Laboratory ValuesTime frame: 32 Weeks

Locations

3 sites in 3 countries. Site status is shown where the registry gives one.

  • Boston Children's Hospital

    Boston, Massachusetts

  • UOS Gastroenterolgia e Riabilitazione nutrizionale Piazza Sant' Onofrio 4

    Rome, Italy

  • Al Jalila Children's Hospital

    Dubai, United Arab Emirates

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.